BioMarin Pharmaceutical Inc. is a biotechnology company. The company is engaged in the development of therapies designed to treat rare/ultra-rare genetic diseases. The company has multiple commercialized products, including therapies for Lambert Myasthenic Syndrome (LEMS), MPS I, MPS VI, MPS IV A and phenylketonuria (PKU) as well as a pipeline that includes a variety of clinical and preclinical product candidates.